The kit allows individuals to test for up to eight species of gastrointestinal parasites at once, with rapid and accurate results, according to a July 28 press release.
Genetic Signatures said that following the trial, it hopes to submit for FDA 510(k) clearance by late 2022.
According to the release, more than 350 million cases of gastrointestinal infections are reported in the U.S. annually, and these parasites can lead to serious infection or even death.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.